News
On Monday, TD Cowen maintained a positive outlook on Day One Biopharmaceuticals shares (NASDAQ: DAWN), reiterating a Buy rating and a price target of $34.00. The firm’s analysis suggests that Day ...
On Monday, TD Cowen maintained a positive outlook on Day One Biopharmaceuticals shares (NASDAQ: DAWN), reiterating a Buy rating and a price target of $34.00.The firm’s analysis suggests that Day ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback